On September 23, 2025, the FDA granted approval for JAVADIN™, the first and only FDA-approved, ready-to-use clonidine oral solution for the control of hypertension in adult patients. Developed by Azurity Pharmaceuticals, JAVADIN™ offers a precise and convenient dosing option for clinicians, addressing a longstanding need for standardized clonidine formulations in hypertension management.

Azurity partnered with Brandsymbol’s Regulatory Division to conduct an independent U.S. Risk Assessment as part of their regulatory readiness process.

Brandsymbol evaluated the proposed name JAVADIN™ through a comprehensive risk assessment designed to identify potential look-alike and sound-alike concerns within the FDA database.

The name JAVADIN™ was recommended following assessment, with findings indicating no significant overlap or safety concerns relative to existing drug names. This validation provided Azurity with the confidence to advance the name for FDA submission, reinforcing their commitment to patient safety and regulatory excellence.

Learn how Brandsymbol’s U.S. Risk Assessment expertise supports safe and compliant drug name approvals.

FDA Approves JAVADIN™: Azurity’s Ready-to-Use Clonidine Oral Solution for Adult Hypertension.